View conference programme - The British Society for Rheumatology

33 FATAL EXACERBATION OF RHEUMATOID ARTHRITIS (RA) ASSOCIATED FIBROSING ALVEOLITIS
IN THREE PATIENTS TREATED WITH AZATHIOPRINE AND INFLIXIMAB.
AJK Ostor 1 , MF Somerville 2 , SE Lane 1 , AYN Lim 1 , AJ Crisp 1 , DGI Scott 2 . 1
Rheumatology Department,
Addenbrooke’s Hospital, Cambridge, Cambs, United Kingdom; 2 Rheumatology Department, Norfolk and
Norwich University Hospital, Norwich, United Kingdom
34 RELATIONSHIP OF ADALIMUMAB (HUMIRA ® ) PHARMACOKINETICS (PK) TO PHARMACODYNAMIC
(PD) IN RHEUMATOID ARTHRITIS (RA) PATIENTS DURING PHASE II/III CLINICAL TRIALS.
R Granneman 1 , Y Zhang 1 , P Noertersheuser 2 , R Velagapudi 3 , W Awni 1 , C Locke 1 , O Segurado 1 , T Toward 4 .
1
Abbott Laboratories, Abbott Park, IL, United States; 2 Abbott Laboratories, Ludwigshafen, Germany;
3
Abbott Laboratories, Parsippany, NJ, United States; 4 Abbott Laboratories, Maidenhead, Berkshire,
United Kingdom
35 THE EFFECT OF DISEASE DURATION ON CLINICAL OUTCOMES FOLLOWING ADALIMUMAB
(HUMIRA ® ) THERAPY IN RA.
P Emery 1 , R Fleischmann 2 , V Strand 3 , WG Reiss 4 , G Spencer-Green 5 , OG Segurado 6 . 1
University of Leeds,
Leeds, United Kingdom; 2 Southwestern Medical Centre at Dallas - Radiant Research, University of Texas,
Dallas, TX, United States; 3 Stanford University, Portola Valley, CA, United States; 4 Abbott Laboratories,
Parsippany, NJ, United States; 5Abbott Laboratories, Chicago, IL, United States
36 BIOLOGICS IN CLINICAL PRACTICE - BETTER THAN EXPECTED?
RN Jois, M Somerville, A Brooksby, K Gaffney, P Merry, DGI Scott. Department of Rheumatology,
Norfolk and Norwich University Hospital, Norwich, United Kingdom
37 ARE ALL ANTI-TNF AGENTS EQUAL? RESULTS OF MERSEY BIOLOGICS AUDIT.
TC Barnes 1 , V Abernethy 2 . 1
Dept Rheumatology, Royal Liverpool University Hospital, Liverpool, United
Kingdom; 2 Dept Rheumatology, Whiston and St Helens Hospital, St. Helens, United Kingdom
38 ANTI TNF: PATIENTS, POLITICS AND PRACTICALITIES OF ACCESS TO TREATMENT DURING
THE LAST FOUR YEARS.
MF Somerville, A Brooksby, K Gaffney, DGI Scott. Rheumatology Unit, Norfolk & Norwich University
Hospital, Norwich, Norfolk, United Kingdom
39 STEADY-STATE ADALIMUMAB (HUMIRA ® ) PHARMACOKINETICS (PK) FOLLOWING EVERY OTHER
WEEK (EOW) DOSING OF 40mg SUBCUTANEOUS (SC) INJECTION, IN RHEUMATOID ARTHRITIS (RA)
PATIENTS TREATED WITH AND WITHOUT CONCOMITANT METHOTREXATE (MTX).
WM Awni 1 , P Cascella 2 , N Oleka 3 , RB Velagapudi 3 , H Kupper 4 , E Chartash 3 , R Granneman 1 ,
OG Segurado 1 , TJ Toward 5 . 1 Abbott Laboratories, Abbott Park, IL, United States; 2 Drug Development
Resources LLC, Mountain Lakes, NJ, United States; 3 Abbott Laboratories, Parsippany, NJ, United States;
4
Abbott Laboratories, Ludwigshafen, Germany; 5 Abbott Laboratories, Maidenhead, Berks,
United Kingdom
40 SUSTAINED EFFICACY OF ADALIMUMAB (HUMIRA ® ) PLUS METHOTREXATE (MTX)
IN RHEUMATOID ARTHRITIS (RA) PATIENTS.
MH Schiff 1 , M Weisman 2 , DE Furst 3 , A Kavanaugh 4 , G Spencer-Green 5 , OG Segurado 6 . 1
Denver Arthritis
Clinic, Denver, CO, United States; 2 Cedars-Sinai Medical Center, Los Angeles, CA, United States; 3 UCLA,
Los Angeles, CA, United States; 4 The Center for Innovative Therapy, UCSD, San Diego, CA, United
States; 5 Abbott Laboratories, Parsippany, NJ, United States; 6 Abbott Laboratories, Chicago, IL,
United States
41 HOW WELL DO WE IDENTIFY RHEUMATOID ARTHRITIS (RA) PATIENTS ELIGIBLE FOR ANTI-TNF
IN OUR ROUTINE CLINICS?
M Leach, S Christy-Kilner, B Pal, PA Sanders. Department of Rheumatology, South Manchester University
Hospitals, Manchester, M20 2LR, United Kingdom
38